Provided by Tiger Fintech (Singapore) Pte. Ltd.

Purple Biotech Ltd.

2.58
-0.1100-4.10%
Post-market: 2.50-0.0748-2.90%16:37 EDT
Volume:12.75K
Turnover:33.22K
Market Cap:6.82M
PE:-0.58
High:2.74
Open:2.74
Low:2.50
Close:2.69
Loading ...

Company Profile

Company Name:
Purple Biotech Ltd.
Exchange:
NASDAQ
Establishment Date:
1968
Employees:
9
Office Location:
4 Oppenheimer Street,Science Park,Rehovot,Israel
Zip Code:
7670104
Fax:
972 3 509 7196
Introduction:
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Directors

Name
Position
Eric Rowinsky
Independent Director and Chairman of the Board of Director
Isaac Israel
Chief Executive Officer and Director
Ido Agmon
Independent Director
Ran Tzror
Independent Director
Revital Stern Raff
Independent Director
Steven Steinberg
Independent Director
Simcha Rock
Director

Shareholders

Name
Position
Isaac Israel
Chief Executive Officer and Director
Gil Efron
Deputy CEO and Chief Financial Officer
Bertrand Liang
Chief Medical Officer
Gil Ben Menachem
Vice President of Business Development
Hadas Reuveni
Vice President or Research and Development
Michael Schickler
Head of Clinical Operations